Latest From Haemonetics Corp.
While a panel of US FDA experts agreed that pathogen reduction technology is a promising strategy for reducing blood platelet contaminations, they raised concerns about the cost of implementing the technology. The maker of the technology, Cerus, says the panel was under-briefed and distracted.
Device industry news on Dec. 2 includes an IDE approval to study a super-small neurostimulator to treat face pain; distribution agreements in diabetes and blood processing; a product approval; and new legislation focused on telemedicine.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Diagnostic Equipment & Supplies
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- Haemonetics Corp.
- Senior Management
Christopher Simon, Pres. & CEO
William Burke, EVP, CFO
- Contact Info
Phone: (781) 848-7100
125 Summer St.
Boston, MA 02110
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.